We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

QIAGEN, Astellas CDx Partnership


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "QIAGEN, Astellas CDx Partnership "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

QIAGEN N.V. announced a master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications or biomarkers, thereby giving Astellas access to QIAGEN’s development capabilities for assays based on PCR, NGS and multi-modal testing technologies using liquid and tissue biopsies. Two initial projects in the collaboration focus on oncology and aim to pair QIAGEN diagnostics with Astellas compounds in early-stage clinical trials: ASP5878, a fibroblast growth factor receptor (FGFR) inhibitor, and ASP8273, an EGFR inhibitor. Financial terms were not disclosed.

“We are very pleased to partner with Astellas to help maximize the benefits of their innovative new drugs with companion diagnostics from our development and commercialization engine. QIAGEN shares Astellas’ commitment to contribute actively toward improving the health of patients by realizing the benefits of personalized healthcare,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “With the master agreement and the first two projects to be disclosed, QIAGEN is further expanding its leadership in personalized medicine – including in Japan, one of the world's largest markets for companion diagnostics. The master agreement provides Astellas and QIAGEN flexibility and a strong foundation to add further development projects across other therapeutic areas, across analytical techniques, and across a broad array of sampling options.”

Advertisement